

Cell Reports Medicine, Volume 5

Supplemental information

**One-third of amenorrheic transmasculine people
on testosterone ovulate**

Joyce D. Asseler, Julieta S. del Valle, Susana M. Chuva de Sousa Lopes, Marieke O. Verhoeven, Mariette Goddijn, Judith A.F. Huirne, and Norah M. van Mello

Table S1. Data on prior GnRHa users of study cohort, related to Table 1.

	Age at GAS, years	Age at start GnRHa, years	Total time on GnRHa, months	Indication GnRHa	Tanner stage at time start GnRHa	Time of GnRHa cessation prior to GAS, months	Histological signs of recent ovulatory activity
1	20	14	40	PS	Unknown	30	Yes, corpus luteum and corpus albicans
2	19	14	19	PS	M4P5	35	Yes, corpus luteum and corpus albicans
3	20	16	14	PS	M5P5	22	Yes, corpus albicans
4	21	17	9	PS	M5P5	40	Yes, corpus luteum
5	20	17	11	PS	M5P5	23	Yes, corpus luteum
6	18	13	47	PS	M3P3	9	No
7	18	16	19	PS	M5P5	8	No
8	21	17	26	PS	M5P5	18	No
9	19	17	12	PS	M5P5	25	No
10	28	26	4	B	N/a	18	No
11	19	11	49	PS	M4P5	42	No
12	21	17	12	PS	M5P5	40	No
13	19	16	36	PS	Unknown	7	No
14	19	12	50	PS	M3P2	31	No
15	18	12	55	PS	M3P4	19	No

Abbreviations used in table: GnRHa = gonadotropin-releasing hormone agonist, PS = puberty suppressant, N/a = not applicable, B: persistent blood loss.